VAX-31 (Vaxcyte)

VAX-31 is an investigational 31-valent pneumococcal conjugate vaccine (PCV) candidate being developed by Vaxcyte, Inc. for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae. Designed to provide the broadest serotype coverage of any PCV in clinical development, VAX-31 covers approximately 95% of IPD and 88% of pneumococcal pneumonia in U.S. adults aged 50 and older. The vaccine is produced using Vaxcyte's proprietary XpressCF cell-free protein synthesis platform, which allows for a carrier-sparing approach to conjugate 31 different capsular polysaccharides. This technology is intended to overcome the limitations of conventional conjugate vaccines by maintaining immunogenicity across a high number of serotypes without overloading the immune system with carrier proteins. VAX-31 has received FDA Breakthrough Therapy Designation for the prevention of IPD and pneumonia in adults and is currently undergoing Phase 3 clinical evaluation in adults and Phase 2 evaluation in infants.

Other names

31-valent pneumococcal conjugate vaccineVAX31VAX-31VAX 31